These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 20542718)

  • 1. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
    Saint Marcoux B; De Bandt M;
    Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis.
    Brocq O; Millasseau E; Albert C; Grisot C; Flory P; Roux CH; Euller-Ziegler L
    Joint Bone Spine; 2009 Jul; 76(4):350-5. PubMed ID: 19362504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
    Wendling D; Cedoz JP; Racadot E
    Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis.
    Balandraud N; Guis S; Meynard JB; Auger I; Roudier J; Roudier C
    Arthritis Rheum; 2007 Jun; 57(5):762-7. PubMed ID: 17530675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and clinical effects of anti-TNFalpha treatment.
    Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
    Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.
    Wendling D; Streit G; Toussirot E; Prati C
    Joint Bone Spine; 2008 Oct; 75(5):540-3. PubMed ID: 18674945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.
    Wendling D; Balblanc JC; Briançon D; Brousse A; Lohse A; Deprez P; Humbert P; Aubin F
    Joint Bone Spine; 2008 May; 75(3):315-8. PubMed ID: 18329935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
    Krintel SB; Essioux L; Wool A; Johansen JS; Schreiber E; Zekharya T; Akiva P; Ostergaard M; Hetland ML
    PLoS One; 2012; 7(6):e38539. PubMed ID: 22685579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.